Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Medicinal application of pristimerin as inflammatory cytokine inhibitor

Inactive Publication Date: 2012-01-11
JIAXING UNIV +1
View PDF2 Cites 7 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

No literature has been found on the effects of physesine on pro-inflammatory cytokines such as TNF-α, IL-6, chemotactic cytokine IL-8, and reactive oxygen species

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Medicinal application of pristimerin as inflammatory cytokine inhibitor
  • Medicinal application of pristimerin as inflammatory cytokine inhibitor
  • Medicinal application of pristimerin as inflammatory cytokine inhibitor

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0021] Example 1 Prissine inhibits the release of TNF-α, IL-8 and IL-6 in vitro

[0022] Cell culture: use RPMI 1640 culture medium containing 10% fetal bovine serum for THP-1 cell line, add penicillin 100U / mL, streptomycin 100U / mL, place at 37°C, 5% CO 2 Cultured in an incubator.

[0023] Determination of cytokine (TNF-α, IL-6 and IL-8) content: THP-1 cells were counted as 1×10 6 / mL inoculated in a 48-well plate, divided into blank control group (DMSO), LPS group (without adding test samples), physesine group (0.15 μM, 0.3 μM and 0.6 μM) and sub-methasone (Dex) group, 3 parallel wells for each sample. After 4 hours of treatment with pristimerin and Dex, except for the blank control group, 1 μg / mL LPS was added to each well for 12 hours, and the supernatant was collected by centrifugation for the determination of TNF-α, IL-6 and IL-8. Calculate the inhibition rate using the following formula:

[0024]

[0025] The results are shown in Tables 1-3.

[0026] Table 1 phys...

Embodiment 2

[0037] Embodiment 2 physesine inhibits active oxygen free radicals

[0038] Cell culture: use RPMI 1640 culture medium containing 10% fetal bovine serum for THP-1 cell line, add penicillin 100U / mL, streptomycin 100U / mL, place at 37°C, 5% CO 2 Cultured in an incubator.

[0039] Determination of ROS (active oxygen molecule) content: THP-1 cells 1×10 6 / mL inoculated in a 24-well plate, and each group was paralleled to 4 wells. The blank control group (DMSO) and the LPS group (without the test sample) were added with the same amount of solvent, and the pristimerin group was added with 0.15 μM, 0.3 μM and 0.6μM prissine, incubated for 2h, except for the blank control group, added 1μg / mL LPS to each well for 12h, then added 5μM DHR 123 (dihydrorhodamine 123) to each well and incubated for 30min, collected cells, and flowed The cytometry was performed and the results are shown in Table 4.

[0040] Table 4 Effect of physesine on ROS generation

[0041]

[0042]

[0043] Rem...

Embodiment 3

[0045] The influence of embodiment 3 physesine on THP-1 cytotoxicity

[0046] Cell culture: use RPMI 1640 culture medium containing 10% fetal bovine serum for THP-1 cell line, add penicillin 100U / mL, streptomycin 100U / mL, place at 37°C, 5% CO 2 Cultured in an incubator.

[0047] Method: 1×10 4 The cells / well were inoculated in 96-well plates, 0.15 μM, 0.3 μM and 0.6 μM physgenin were added to the administration group, and the same amount of solvent was added to the cells in the blank control group, and cultured at 37 ° C. After 12 hours, each well was added 10 μL of MTT (5mg / mL), after co-incubating for 4 hours, the activity of succinate dehydrogenase in living cells was measured, and the OD value was measured at 490nm, and the results were expressed as inhibition rate. The experimental results are shown in Table 5.

[0048] The influence of table 5 physesine on the proliferation of THP-1 cells

[0049]

[0050] The experimental results showed that prissine had no obvio...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses the application of pristimerin to preparation of an inflammatory cytokine inhibitor, in particular application of the pristimerin to treatment of symptoms related to excessive secretion of TNF-alpha, IL-6 and IL-8, and / or application of pristimerin to the aspect of active oxygen free radical inhibitors.

Description

technical field [0001] The present invention relates to the application of physesine. Background technique [0002] Inflammation is the body's defense response to various stimuli, and it is also the last common path of infection, trauma, and allergic reactions. The main feature of inflammation is the recruitment of a large number of inflammatory cells, the activation of pro-inflammatory cells, and the production of a large number of pro-inflammatory cells through the body's immune system. Factors and active oxygen free radicals with inflammatory properties. The cells closely related to the occurrence and development of inflammatory diseases are mainly monocytes / macrophages. Pro-inflammatory cytokines and reactive oxygen species are mainly secreted by monocytes / macrophages, and can amplify the inflammatory response through the inflammatory network and damage local tissues. Pro-inflammatory cytokines such as interleukin IL-6, TNF-α and IL-8 are most closely related to inflam...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/56A61P29/00A61P43/00A61P19/04A61P19/08A61P1/00A61P9/04A61P3/10A61P37/02A61P17/00A61P17/06A61P35/02A61P25/16A61P25/28A61P25/24A61P11/00A61P11/06A61P25/00A61P31/12A61P35/00A61P37/06A61P1/02A61P31/04A61P3/04A61P25/04A61P25/06A61P9/10A61P31/18A61P1/18A61P13/12A61P7/08
Inventor 惠斌惠玲张立萍吴达龙吴强陈国良宋国杰姚鑫陆国明
Owner JIAXING UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com